In our study, a moderate sensitivity of 69.2% was achieved for identifying plasma EGFR mutations via both cfDNA assays, consistent with previous studies [23,25], which suggests that plasma EGFR mutations might be highly predictive of identical mutations in corresponding tumor tissues. Here, EGFR is linked to neoplasm.